Current Treatment Options in Oncology

, Volume 14, Issue 1, pp 22–33

Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer

Gynecologic Cancers (RJ Morgan, Section Editor)

DOI: 10.1007/s11864-012-0220-6

Cite this article as:
Han, E.S., Wakabayashi, M. & Leong, L. Curr. Treat. Options in Oncol. (2013) 14: 22. doi:10.1007/s11864-012-0220-6

Opinion statement

Treatment of epithelial ovarian cancer involves surgical management with staging or debulking surgery and chemotherapy with a platinum and taxane-containing regimen. Despite achieving a 70–80 % complete remission, patients often will recur. Novel therapies are needed to improve the treatment of ovarian cancers. Tumor angiogenesis is a critical process involved in the growth and metastasis of ovarian cancer. Numerous phase II trials with angiogenesis inhibitors have been reported and have led to the development and completion of several recent phase III trials in both upfront and recurrent ovarian cancers. Future studies will need to focus on how and when to incorporate angiogenesis inhibitors in the treatment armamentarium for ovarian cancers.


Ovarian cancerAngiogenesisVEGF

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ernest S. Han
    • 1
  • Mark Wakabayashi
    • 1
  • Lucille Leong
    • 2
  1. 1.Department of SurgeryDivision of Gynecologic OncologyDuarteUSA
  2. 2.Department of Medical Oncology and Therapeutics ResearchDuarteUSA